Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

This study group evaluated if IFNB-1b in people with clinically isolated syndrome (CIS) prevented persisting T1 hypointensities on MRI (persistent black holes (PBHs)). Patients were randomised to IFNB-1b (n=292) or placebo (n=176) in the placebo-controlled phase for two years. In the open-label phase (n=418), both groups were offered IFNB-1b for up to five years. The researchers found that the number of PBHs was lower in the early treatment arm than the delayed arm during both phases. Overall the rate of lesions which converted to PBH showed no significant differences between groups. The researchers did find that the number of PBHs per patient out of new lesions was significantly lower in IFNB-1b patients compared to patients on placebo.
Authors: Nagtegaal GJ, Pohl C
Source: Mult Scler. 2013 Jul 10. [Epub ahead of print]
Read the abstract  

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial